Investor · 1 deal
Every published round Professor Ian Charles took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Longas | Unnamed stage | 16 May 2019 | - | Participant | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Companies Professor Ian Charles has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Longas | 16 May 2019 | 1 | 0 |
Fund closes reported for Professor Ian Charles, as distinct from the investments it has made.
Companies Professor Ian Charles has backed that another company then bought. An exit for the holding, not a deal Professor Ian Charles did.
Stories naming Professor Ian Charles. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Australian genomics spin-out Longas has come out of stealth with technology that extends DNA sequencing read length, backed by the MRCF and its founders, and appoints Solexa's founding chief executive Nick McCooke as CEO.
A university spin-out launches with venture and founder backing, introducing a technology that extends DNA sequencing read lengths, and appointing a new chief executive to commercialise it.